B7-H3 and ICAM-1 are potentially therapeutic targets for thyroid carcinoma.

IF 2.3 3区医学 Q2 PATHOLOGY Diagnostic Pathology Pub Date : 2024-06-10 DOI:10.1186/s13000-024-01504-2

Pengtao Song, Yongcan Xu, Guochao Ye

{"title":"B7-H3 and ICAM-1 are potentially therapeutic targets for thyroid carcinoma.","authors":"Pengtao Song, Yongcan Xu, Guochao Ye","doi":"10.1186/s13000-024-01504-2","DOIUrl":null,"url":null,"abstract":"<p><p>Although most differentiated thyroid carcinoma has a clinically favorable prognosis, some of specific types of thyroid cancer (such as anaplastic thyroid carcinoma and advanced papillary thyroid carcinoma) show fatal outcomes and require novel treatments. Immunotherapy is a promising avenue for the treatment of advanced thyroid carcinoma. B7-H3 (B7 homolog 3 protein) and ICAM-1 (intercellular adhesion molecule 1), as two important immune checkpoints (ICPs), is becoming hopeful target spots for immunotherapy. A growing amount of evidence has suggested that B7-H3 and ICAM-1 are upregulated in papillary thyroid carcinoma. However, their expression level in specific types of thyroid cancer remains largely unclear. In the present study, we explored the expression level of B7-H3 and ICAM-1 in different types of thyroid carcinoma. In the groups of the TCGA cohort, both B7-H3 and ICAM-1 mRNA were highly expressed in thyroid carcinoma. Furthermore, the patients with Stage2, 61-80y, Follicular thyroid papillary carcinoma and N0 had lower B7-H3 and ICAM-1 mRNA expression. In the groups of our cohort, PTCs and ATCs showed frequently moderate to strong expression of B7-H3 and ICAM-1 protein expression. The significant relevance of B7-H3 staining score with ICAM-1 staining score was observed in TCGA database and our cohort, which might open avenues for the combination therapy in advanced thyroid cancer.</p>","PeriodicalId":11237,"journal":{"name":"Diagnostic Pathology","volume":"19 1","pages":"77"},"PeriodicalIF":2.3000,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11163747/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diagnostic Pathology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13000-024-01504-2","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PATHOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Although most differentiated thyroid carcinoma has a clinically favorable prognosis, some of specific types of thyroid cancer (such as anaplastic thyroid carcinoma and advanced papillary thyroid carcinoma) show fatal outcomes and require novel treatments. Immunotherapy is a promising avenue for the treatment of advanced thyroid carcinoma. B7-H3 (B7 homolog 3 protein) and ICAM-1 (intercellular adhesion molecule 1), as two important immune checkpoints (ICPs), is becoming hopeful target spots for immunotherapy. A growing amount of evidence has suggested that B7-H3 and ICAM-1 are upregulated in papillary thyroid carcinoma. However, their expression level in specific types of thyroid cancer remains largely unclear. In the present study, we explored the expression level of B7-H3 and ICAM-1 in different types of thyroid carcinoma. In the groups of the TCGA cohort, both B7-H3 and ICAM-1 mRNA were highly expressed in thyroid carcinoma. Furthermore, the patients with Stage2, 61-80y, Follicular thyroid papillary carcinoma and N0 had lower B7-H3 and ICAM-1 mRNA expression. In the groups of our cohort, PTCs and ATCs showed frequently moderate to strong expression of B7-H3 and ICAM-1 protein expression. The significant relevance of B7-H3 staining score with ICAM-1 staining score was observed in TCGA database and our cohort, which might open avenues for the combination therapy in advanced thyroid cancer.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

B7-H3 和 ICAM-1 是甲状腺癌的潜在治疗靶点。

虽然大多数分化型甲状腺癌的临床预后良好，但一些特定类型的甲状腺癌（如无细胞甲状腺癌和晚期甲状腺乳头状癌）却显示出致命的结果，需要采用新的治疗方法。免疫疗法是治疗晚期甲状腺癌的一个前景广阔的途径。B7-H3（B7同源物3蛋白）和ICAM-1（细胞间粘附分子1）作为两个重要的免疫检查点（ICP），正成为免疫疗法的希望靶点。越来越多的证据表明，B7-H3和ICAM-1在甲状腺乳头状癌中上调。然而，它们在特定类型甲状腺癌中的表达水平在很大程度上仍不清楚。在本研究中，我们探讨了B7-H3和ICAM-1在不同类型甲状腺癌中的表达水平。在TCGA队列中，B7-H3和ICAM-1 mRNA在甲状腺癌中均有高表达。此外，2期、61-80岁、滤泡状甲状腺乳头状癌和N0患者的B7-H3和ICAM-1 mRNA表达量较低。在我们的队列中，PTC 和 ATC 常常有中度到高度的 B7-H3 和 ICAM-1 蛋白表达。在TCGA数据库和我们的队列中观察到，B7-H3染色评分与ICAM-1染色评分有明显的相关性，这可能为晚期甲状腺癌的联合治疗开辟了道路。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Diagnostic Pathology 医学-病理学

CiteScore

4.60

自引率

0.00%

发文量

审稿时长

1 months

期刊介绍： Diagnostic Pathology is an open access, peer-reviewed, online journal that considers research in surgical and clinical pathology, immunology, and biology, with a special focus on cutting-edge approaches in diagnostic pathology and tissue-based therapy. The journal covers all aspects of surgical pathology, including classic diagnostic pathology, prognosis-related diagnosis (tumor stages, prognosis markers, such as MIB-percentage, hormone receptors, etc.), and therapy-related findings. The journal also focuses on the technological aspects of pathology, including molecular biology techniques, morphometry aspects (stereology, DNA analysis, syntactic structure analysis), communication aspects (telecommunication, virtual microscopy, virtual pathology institutions, etc.), and electronic education and quality assurance (for example interactive publication, on-line references with automated updating, etc.).